The global Antibody Drug Conjugate Market size is expected to
reach USD 9.93 billion by 2025, according to a new report by Grand View
Research, Inc. it is projected to expand at a CAGR of 25.9% over the forecast
period. Increasing incidence of cancer coupled with growing geriatric
population are likely to drive the market for Antibody-Drug Conjugates (ADC).
Furthermore, major technological advancements are also contributing to drive
the growth. According to the World Health Organization (WHO), the number of
people aged 65 years and above, is projected to reach 16% of the total
population by 2050 from 7% in 2000. Aging has become a substantial risk factor
for numerous diseases including cancer and others. Hence, the growing geriatric
population is expected to drive growth of the market over the forecast period.
Until 2018, four ADCs were
available in the market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due
to appropriate targeting and improved technology, ADCs have been gaining a lot
of attention from both small and large pharmaceutical companies. Currently
there are more than 50 ADCs in clinical trials and it has been projected that
during the forecast period three to four ADCs will be commercialized in the
area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer,
breast cancer, and ovarian cancer. It has been observed that the maximum number
of clinical trials are being conducted for lymphoma.
Seattle Genetics and Roche are
leading the antibody drug conjugate market in terms of market share. Until 2017
only two ADCs were commercially available-Adcetris by Seattle Genetics and
Kadcyla by Roche. Recently, two more Pfizer’s products were approved to be
marketed for acute myeloid leukaemia and acute lymphoblastic leukaemia. Hence,
it has been estimated that over the forecast period, Pfizer is anticipated to
gain a significant market share.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market
Further key findings from the report suggest:
- Breast cancer was the largest segment in 2017
and is likely to witness a significant growth over the forecast period due
to the factors such as availability of Kadcyla and high prevalence of
breast cancer
- Cleavable linker is expected to witness the
fastest growth over the forecast period as the maximum product in the
pipeline contains cleavable linkers. In addition, in 2017 two new
products-Besponsa and Mylotarg were approved in the market
- In 2017, North America was the largest revenue
generating region in the antibody-drug conjugates market. It is the most
well-established regions in terms of patient awareness and usage of ADCs
and makes up most of the existing market
- The players operating in this space are F.
Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda
Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen
Inc.
- Market players are adopting strategies, such as
introducing technologically advanced products, collaborations, and
geographic expansions to increase their market share. For instance,
Seattle Genetics collaborated with Takeda for developing brentuximab
vedotin (Adcetris) for refractory/relapsed Hodgkin lymphoma.
Grand View Research has
segmented the global antibody drug conjugate market on the basis of
application, technology, and region:
Antibody Drug Conjugate Application Outlook (Revenue, USD
Million, 2014 - 2025)
- Blood Cancer
- Leukemia
- Lymphoma
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Brain Tumor
Antibody Drug Conjugate Technology Outlook (Revenue, USD
Million, 2014 - 2025)
- Cleavable Linker
- Non-cleavable Linker
Antibody Drug Conjugate Regional Outlook (Revenue, USD
Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Middle East & Africa
- South Africa
- About Grand View Research, Inc.:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: http://www.grandviewresearch.com
No comments:
Post a Comment